Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509210 · ClinicalTrials.gov registry record · Phase 1
Study of Telaprevir in Subjects With Hepatic Impairment
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00509210: Completed Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT00509210 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509210, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.
Interventions
- DRUG telaprevir (VX-950)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
What the finished NCT00509210 record still lists
NCT00509210 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which telaprevir (VX-950) is the first listed.
NCT00509210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00509210 about?
NCT00509210 is a clinical study titled "Study of Telaprevir in Subjects With Hepatic Impairment". The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.
What is the current status of trial NCT00509210?
This trial is currently completed. It is a Phase 1 study. The study started on 2007-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00509210?
The interventions under investigation include: telaprevir (VX-950) (DRUG).
Who is sponsoring clinical trial NCT00509210?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia